AR094452A1 - COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa - Google Patents
COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFaInfo
- Publication number
- AR094452A1 AR094452A1 ARP130104091A ARP130104091A AR094452A1 AR 094452 A1 AR094452 A1 AR 094452A1 AR P130104091 A ARP130104091 A AR P130104091A AR P130104091 A ARP130104091 A AR P130104091A AR 094452 A1 AR094452 A1 AR 094452A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- heteroatoms selected
- carbon atoms
- case
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), o un estereoisómero o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde Y es N o CR⁶; R¹ se selecciona de H, alquilo C₁₋₃ o cicloalquilo C₃₋₆, cada uno opcionalmente sustituido con 0 - 7 R¹ᵃ; R¹ᵃ es, en cada caso, independientemente hidrógeno, deuterio, F, Cl, Br o CN; R² es -C(O)R²ᵃ; o alquilo C₁₋₆, -(CH₂)ʳ-carbociclo de 3 - 14 miembros sustituido con 0 - 1 R²ᵃ o un heterociclo de 5 - 14 miembros que contiene 1 - 4 heteroátomos seleccionados de N, O y S, cada grupo sustituido con 0 - 4 R²ᵃ; R²ᵃ es, en cada caso, independientemente hidrógeno, =O, halo, OCF₃, CN, NO₂, -(CH₂)ʳORᵇ, -(CH₂)ʳSRᵇ, -(CH₂)ʳC(O)Rᵇ, -(CH₂)ʳC(O)ORᵇ, -(CH₂)ʳOC(O)Rᵇ, -(CH₂)ʳNR¹¹R¹¹, -(CH₂)ʳC(O)NR¹¹R¹¹, -(CH₂)ʳNRᵇC(O)Rᶜ, -(CH₂)ʳNRᵇC(O)ORᶜ, -NRᵇC(O)NR¹¹R¹¹, -S(O)ₚNR¹¹R¹¹, NRᵇS(O)ₚRᶜ, S(O)ₚRᶜ, alquilo C₁₋₆ sustituido con 0 - 3 Rᵃ, haloalquilo C₁₋₆, alquenilo C₂₋₆ sustituido con 0 - 3 Rᵃ, alquinilo C₂₋₆ sustituido con 0 - 3 Rᵃ, -(CH₂)ʳ-carbociclo de 3 - 14 miembros sustituido con 0-1 Rᵃ o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono o 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 2 Rᵃ; R³ es cicloalquilo C₃₋₁₀, arilo C₆₋₁₀ o un heterociclo de 5 - 10 miembros que contiene 1 - 4 heteroátomos seleccionados de N, O y S, cada grupo sustituido con 0 - 4 R³ᵃ; R³ᵃ es, en cada caso, independientemente hidrógeno, =O, halo, OCF₃, CF₃, CHF₂, CN, NO₂, -(CH₂)ʳORᵇ, -(CH₂)ʳSRᵇ, -(CH₂)ʳC(O)Rᵇ, -(CH₂)ʳC(O)ORᵇ, -(CH₂)ʳOC(O)Rᵇ, -(CH₂)ʳNR¹¹R¹¹, -(CH₂)ʳC(O)NR¹¹R¹¹, -(CH₂)ʳNRᵇC(O)Rᶜ, -(CH₂)ʳNRᵇC(O)ORᶜ, -NRᵇC(O)NR¹¹R¹¹, -S(O)ₚNR¹¹R¹¹, -NRᵇS(O)ₚRᶜ, -S(O)ₚRᶜ, alquilo C₁₋₆ sustituido con 0 - 3 Rᵃ, alquenilo C₂₋₆ sustituido con 0 - 3 Rᵃ, alquinilo C₂₋₆ sustituido con 0 - 3 Rᵃ, haloalquilo C₁₋₆, -(CH₂)ʳ-carbociclo de 3 - 14 miembros sustituido con 0 - 3 Rᵃ o -(CH₂)ʳ-heterociclo de 5 - 10 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 3 Rᵃ; o dos R³ᵃ, junto con los átomos a los que están unidos, se combinan para formar un anillo fusionado, en donde el anillo se selecciona de fenilo y un heterociclo que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ, y cada anillo fusionado se sustituye con 0 - 3 Rᵃ¹; R⁴ y R⁵ son independientemente hidrógeno, alquilo C₁₋₄ sustituido con 0 - 1 Rᶠ, (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᵈ o -(CH₂)-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ; R⁶ es hidrógeno, halo, alquilo C₁₋₄, haloalquilo C₁₋₄, O-haloalquilo C₁₋₄, O-alquilo C₁₋₄, CN, NO₂ u OH; R¹¹ es, en cada caso, independientemente hidrógeno, alquilo C₁₋₄ sustituido con 0 - 3 Rᶠ, CF₃, un cicloalquilo C₃₋₁₀ sustituido con 0 - 1 Rᶠ, (CH)ʳ-fenilo sustituido con 0 - 3 Rᵈ o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ, sustituido con 0 - 3 Rᵈ; Rᵃ y Rᵃ¹ son, en cada caso, independientemente hidrógeno, F, Cl, Br, OCF₃, CF₃, CHF₂, CN, NO₂, -(CH₂)ʳORᵇ, -(CH₂)ʳSRᵇ, -(CH₂)ʳC(O)Rᵇ, -(CH₂)ʳC(O)ORᵇ, -(CH₂)ʳOC(O)Rᵇ, -(CH₂)ʳNR¹¹R¹¹, -(CH₂)ʳC(O)NR¹¹R¹¹, -(CH₂)ʳNRᵇC(O)Rᶜ, -(CH₂)ʳNRᵇC(O)ORᶜ, -NRᵇC(O)NR¹¹R¹¹, -S(O)ₚNR¹¹R¹¹, -NRᵇS(O)ₚRᶜ, -S(O)Rᶜ, -S(O)₂Rᶜ, alquilo C₁₋₆ sustituido con 0 - 3 Rᶠ, haloalquilo C₁₋₆, alquenilo C₂₋₆ sustituido con 0 - 3 Rᵃ, alquinilo C₂₋₆ sustituido con 0 - 3 Rᵃ, -(CH₂)ʳ-carbociclo de 3 - 14 miembros o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 3 Rᶠ; Rᵇ es hidrógeno, alquilo C₁₋₆ sustituido con 0 - 3 Rᵈ, haloalquilo C₁₋₆, cicloalquilo C₃₋₆ sustituido con 0 - 2 Rᵈ, o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 3 Rᶠ o (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᵈ; Rᶜ es alquilo C₁₋₆ sustituido con 0 - 3 Rᶠ, -(CH₂)ʳ-cicloalquilo C₃₋₆ sustituido con 0 - 3 Rᶠ o (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᶠ; Rᵈ es, en cada caso, independientemente hidrógeno, F, Cl, Br, OCF₃, CF₃, CN, NO₂, -ORᵉ, -(CH₂)ʳC(O)Rᶜ, -NRᵉRᵉ, -NRᵉC(O)ORᶜ, alquilo C₁₋₆ o (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᶠ; Rᵉ se selecciona, independientemente en cada caso, de hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ y (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᶠ; Rᶠ es, en cada caso, independientemente hidrógeno, halo, CN, NH₂, OH, cicloalquilo C₃₋₆, CF₃, O(alquilo C₁₋₆) o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ; p es 0, 1 ó 2; y r es 0, 1, 2, 3 ó 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723840P | 2012-11-08 | 2012-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR094452A1 true AR094452A1 (es) | 2015-08-05 |
Family
ID=49876960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104091A AR094452A1 (es) | 2012-11-08 | 2013-11-07 | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa |
Country Status (38)
Country | Link |
---|---|
US (6) | USRE47929E1 (es) |
EP (3) | EP2922846B1 (es) |
JP (3) | JP6407159B2 (es) |
KR (1) | KR102195194B1 (es) |
CN (1) | CN104884454B (es) |
AR (1) | AR094452A1 (es) |
AU (4) | AU2013341186B2 (es) |
BR (1) | BR112015010102B1 (es) |
CA (1) | CA2890981C (es) |
CL (1) | CL2015001231A1 (es) |
CY (2) | CY1121188T1 (es) |
DK (2) | DK2922846T3 (es) |
EA (1) | EA028814B1 (es) |
ES (2) | ES2702148T3 (es) |
FI (1) | FIC20230028I1 (es) |
FR (1) | FR23C1030I1 (es) |
HK (1) | HK1215255A1 (es) |
HR (2) | HRP20220766T1 (es) |
HU (3) | HUE041750T2 (es) |
IL (1) | IL238610A0 (es) |
LT (3) | LT2922846T (es) |
MA (1) | MA38072A1 (es) |
MX (2) | MX2015005731A (es) |
MY (2) | MY175448A (es) |
NL (1) | NL301238I2 (es) |
NZ (1) | NZ708859A (es) |
PE (1) | PE20150944A1 (es) |
PH (1) | PH12015501004B1 (es) |
PL (2) | PL3495358T3 (es) |
PT (2) | PT3495358T (es) |
RS (2) | RS63328B1 (es) |
SG (3) | SG11201503399XA (es) |
SI (2) | SI2922846T1 (es) |
TR (1) | TR201820824T4 (es) |
TW (1) | TWI605041B (es) |
UY (1) | UY35126A (es) |
WO (1) | WO2014074661A1 (es) |
ZA (1) | ZA201504052B (es) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY35126A (es) * | 2012-11-08 | 2014-05-30 | Bristol Myers Squibb Co | Ojo es alfa |
BR112015009798A2 (pt) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa |
TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
US9834548B2 (en) | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
CA3005159A1 (en) | 2015-11-26 | 2017-06-01 | Novartis Ag | Diamino pyridine derivatives |
TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
CA3040286A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
TW201827423A (zh) * | 2016-12-13 | 2018-08-01 | 美商必治妥美雅史谷比公司 | 做為IL-12, IL-23及/或IFNα反應調節劑之經烷基醯胺取代之雜芳基化合物氧化膦 |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
EP3592746B1 (en) | 2017-03-08 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
EP3601270A1 (en) * | 2017-03-30 | 2020-02-05 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
CN111315737B (zh) | 2017-11-21 | 2024-06-18 | 百时美施贵宝公司 | 经砜吡啶烷基酰胺取代的杂芳基化合物 |
JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ2媒介性シグナル伝達の阻害剤 |
ES2944733T3 (es) * | 2018-03-22 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa |
KR20210015924A (ko) | 2018-05-31 | 2021-02-10 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태 |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
EP3866789A4 (en) | 2018-10-15 | 2022-07-06 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
MX2021004538A (es) | 2018-10-22 | 2021-09-10 | Esker Therapeutics Inc | Inhibidores de tyk2 y sus usos. |
US20230020273A1 (en) * | 2018-10-30 | 2023-01-19 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha |
JP7530360B2 (ja) | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Tyk2阻害剤およびその使用 |
EP3914357A4 (en) | 2019-01-23 | 2022-10-12 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND THEIR USES |
WO2020156311A1 (zh) * | 2019-01-28 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
KR20210121140A (ko) * | 2019-01-30 | 2021-10-07 | 브리스톨-마이어스 스큅 컴퍼니 | 아미드-이치환된 피리딘 또는 피리다진 화합물 |
EP3962475A1 (en) * | 2019-04-30 | 2022-03-09 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
JP2022536489A (ja) | 2019-06-12 | 2022-08-17 | ブリストル-マイヤーズ スクイブ カンパニー | 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶性塩形態 |
CN114364665A (zh) * | 2019-07-16 | 2022-04-15 | 百时美施贵宝公司 | 调节白介素的前药 |
US20220281842A1 (en) * | 2019-08-01 | 2022-09-08 | Integral Biosciences Pvt. Ltd. | Heterocyclic compounds as kinase inhibitor and uses thereof |
AU2020347274A1 (en) | 2019-09-13 | 2022-03-31 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
WO2021055651A1 (en) * | 2019-09-18 | 2021-03-25 | Bristol-Myers Squibb Company | Extended release dosage forms for tyk2 inhibitors |
WO2021129467A1 (zh) * | 2019-12-27 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种bms-986165晶型及其制备方法和用途 |
US20230049130A1 (en) * | 2020-01-19 | 2023-02-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Deucravacitinib crystal form, preparation method therefor and use thereof |
WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
US20230159520A1 (en) * | 2020-02-26 | 2023-05-25 | Beigene, Ltd. | Tyk-2 inhibitor |
HRP20240643T1 (hr) * | 2020-03-11 | 2024-08-02 | Beijing InnoCare Pharma Tech Co., Ltd. | Heterociklički spojevi za inhibiciju aktivnosti tyk2 |
WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
CN113563309A (zh) * | 2020-04-28 | 2021-10-29 | 浙江海正药业股份有限公司 | 吡啶类衍生物及其制备方法和用途 |
EP4143180A1 (en) * | 2020-04-28 | 2023-03-08 | Bristol-Myers Squibb Company | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
CN113735837B (zh) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | 哒嗪类化合物及其用途 |
CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
CN113773262B (zh) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | 哒嗪类化合物 |
CA3186000A1 (en) * | 2020-07-24 | 2022-01-27 | Shanghai Hansoh Biomedical Co., Ltd. | Crystal form of pyridazine derivative free base, and preparation method therefor and use thereof |
EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
CA3192982A1 (en) | 2020-09-18 | 2022-03-24 | Umesh KESTUR | Dosage forms for tyk2 inhibitors comprising swellable cores |
CN116615200A (zh) * | 2020-10-20 | 2023-08-18 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
US20240059671A1 (en) * | 2020-11-12 | 2024-02-22 | Cullgen (Shanghai), Inc. | Tyrosine kinase 2 (tyk2) degradation compounds and methods of use |
WO2022105771A1 (zh) * | 2020-11-17 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类衍生物、其制备方法及其在医药上的应用 |
WO2022121868A1 (zh) * | 2020-12-08 | 2022-06-16 | 正大天晴药业集团股份有限公司 | 含酰胺基和杂环烷基的tyk2抑制剂化合物 |
EP4284796A1 (en) | 2021-01-29 | 2023-12-06 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
US20230113202A1 (en) | 2021-02-02 | 2023-04-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的tyk2抑制劑化合物、藥物組合物及其用途 |
IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | TYK2 inhibitors and uses thereof |
BR112023016590A2 (pt) | 2021-02-19 | 2023-11-14 | Sudo Biosciences Ltd | Inibidores de tyk2 e seus usos |
US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
WO2022193499A1 (en) * | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
EP4313974A1 (en) | 2021-03-29 | 2024-02-07 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
CN117177960A (zh) * | 2021-03-30 | 2023-12-05 | 浙江文达医药科技有限公司 | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 |
CN115197196B (zh) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | Tyk2抑制剂及其用途 |
JP2024517453A (ja) | 2021-05-04 | 2024-04-22 | シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド | 含窒素複素環ピリジン化合物 |
MX2023013445A (es) * | 2021-05-14 | 2023-12-14 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos. |
KR20240007242A (ko) | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
EP4337649A1 (en) | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
KR20240008337A (ko) | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
WO2022253335A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 含磺酰基的芳基类化合物及其应用 |
AU2022298616A1 (en) * | 2021-06-22 | 2024-01-18 | Medshine Discovery Inc. | Sulfoximine compound and use thereof |
EP4371981A1 (en) * | 2021-07-15 | 2024-05-22 | Medshine Discovery Inc. | Sulfur/phosphorus-containing aryl compound and application thereof |
JP2024529763A (ja) | 2021-08-20 | 2024-08-08 | ブリストル-マイヤーズ スクイブ カンパニー | 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体 |
WO2023027948A1 (en) * | 2021-08-21 | 2023-03-02 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
EP4404930A1 (en) | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
WO2023055901A2 (en) | 2021-09-30 | 2023-04-06 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
EP4422690A1 (en) | 2021-10-28 | 2024-09-04 | Bristol-Myers Squibb Company | Topical formulations of deucravacitinib |
WO2023102085A1 (en) | 2021-12-01 | 2023-06-08 | Teva Czech Industries S.R.O. | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
CA3240888A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
CN116693449A (zh) * | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
WO2023231997A1 (zh) * | 2022-05-31 | 2023-12-07 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
WO2024020221A1 (en) | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
TW202416950A (zh) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | 雜芳基甲醯胺及相關gpr84拮抗劑及其用途 |
TW202416972A (zh) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | 經取代之吡啶酮gpr84拮抗劑及其用途 |
WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
WO2024102683A1 (en) | 2022-11-08 | 2024-05-16 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
WO2024127363A1 (en) | 2022-12-16 | 2024-06-20 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
CN116284040B (zh) * | 2023-01-05 | 2024-05-28 | 华润医药研究院(深圳)有限公司 | 含氮杂环类化合物及其医药用途 |
WO2024165000A1 (zh) * | 2023-02-07 | 2024-08-15 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
WO2000075113A1 (fr) | 1999-06-09 | 2000-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives carboxamide heterocycliques |
AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
BR0312738A (pt) | 2002-07-15 | 2007-06-26 | Wyeth Corp | processos e composições para a modulação do desenvolvimento e da função de células t auxiliares (th) |
US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
WO2011113802A2 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
BR112013006016A2 (pt) * | 2010-09-15 | 2016-06-07 | Hoffmann La Roche | compostos de azabenzotiazol, composições e métodos de uso |
MX2013005445A (es) | 2010-11-19 | 2013-07-29 | Hoffmann La Roche | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). |
JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4−トリアジン−6−カルボキサミド誘導体 |
RU2627661C2 (ru) * | 2012-01-10 | 2017-08-09 | Ф. Хоффманн-Ля Рош Аг | Соединения пиридазинамида и их применение в качестве ингибиторов тирозинкиназы селезенки (syk) |
UY34807A (es) * | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
MX2015004801A (es) * | 2012-10-19 | 2015-08-14 | Hoffmann La Roche | Inhibidores de la syk. |
CN104781252B (zh) | 2012-11-08 | 2017-11-17 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物 |
UY35126A (es) * | 2012-11-08 | 2014-05-30 | Bristol Myers Squibb Co | Ojo es alfa |
BR112015009798A2 (pt) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa |
TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
EP3601270A1 (en) | 2017-03-30 | 2020-02-05 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
-
2013
- 2013-11-07 UY UY0001035126A patent/UY35126A/es unknown
- 2013-11-07 SI SI201331219T patent/SI2922846T1/sl unknown
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/hu unknown
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 TW TW102140572A patent/TWI605041B/zh active
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/lt unknown
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/pt active IP Right Grant
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en active Application Filing
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/ko active IP Right Grant
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/ja active Active
- 2013-11-07 PT PT181975509T patent/PT3495358T/pt unknown
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 RS RS20220589A patent/RS63328B1/sr unknown
- 2013-11-07 ES ES13811640T patent/ES2702148T3/es active Active
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/es active IP Right Grant
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/tr unknown
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/en active
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/es active IP Right Grant
- 2013-11-07 ES ES18197550T patent/ES2914793T3/es active Active
- 2013-11-07 MA MA38072A patent/MA38072A1/fr unknown
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 PL PL18197550T patent/PL3495358T3/pl unknown
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/hr unknown
- 2013-11-07 RS RS20181428A patent/RS58187B1/sr unknown
- 2013-11-07 PL PL13811640T patent/PL2922846T3/pl unknown
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 AR ARP130104091A patent/AR094452A1/es active IP Right Grant
- 2013-11-07 EA EA201590917A patent/EA028814B1/ru not_active IP Right Cessation
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/da active
- 2013-11-07 PT PT13811640T patent/PT2922846T/pt unknown
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/lt unknown
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/hu unknown
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/zh active Active
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 SI SI201331986T patent/SI3495358T1/sl unknown
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/es unknown
- 2015-05-06 PH PH12015501004A patent/PH12015501004B1/en unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/es unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-03-21 HK HK16103247.7A patent/HK1215255A1/zh unknown
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/ja active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-11-21 HR HRP20181937TT patent/HRP20181937T1/hr unknown
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/el unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/ja active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en active Pending
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/nl unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/el unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/hu unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I1/fr active Active
- 2023-08-23 LT LTPA2023523C patent/LTPA2023523I1/lt unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
AR113895A1 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR090867A1 (es) | Compuestos y composiciones plaguicidas y procesos relacionados | |
AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
AR088534A1 (es) | Composiciones plaguicidas y procesos relacionados con dichas composiciones | |
AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR085410A1 (es) | Derivados de pirazol heteroaril-sustituidos, composiciones pesticidas que los comprenden y su uso en el control de plagas | |
AR090045A1 (es) | Compuestos de isotiazolina para combatir plagas de invertebrados | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR104555A1 (es) | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
AR108906A1 (es) | Heterociclos de biarilmetilo | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
DOP2011000083A (es) | Compuestos de amida utiles en terapia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |